Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2393-2395

  Hu, Xiaohui ^a   Xu, Jingjing ^a   Sun, Aining ^a   Shen, Yaying ^a   He, Guangsheng ^a   Guo, Feng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BORTEZOMIB; CD3 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; BLAST CELL; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DNA BINDING; DRUG MEGADOSE; DRUG TOLERABILITY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MALE; NF-KAPPA B; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEASE INHIBITORS; PYRAZINES; TREATMENT OUTCOME;

EID: 82255193041     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.593271     Document Type: Letter

References (12)

1. Karin M. NF-kappaB as a critical link between inf ammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141.
2. Paoluzzi L, O'Connor OA. Mechanistic rationale and clinical evidence for the ef cacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 2006;20:13-23.
3. Gil L, Styczynski J, Dytfeld D, et al. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res 2007;27:4021-4025.
4. Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010;16: 554-565.
5. Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008;19:2079-2083.
6. Zhao WL. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 2010;24:13-21.
7. Guo F, Sun A, Wang W, et al. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 2009;46:2441-2448.
8. Guo F, Tanzer S, Busslinger M, Weih F. Lack of nuclear factor-kappa B2/p100 causes a RelB-dependent block in early B lymphopoiesis. Blood 2008;112:551-559.
9. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008;8:380-390. (Pubitemid 351595220)
10. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007;13:70-77. (Pubitemid 46067388)
11. Espinosa L, Cathelin S, D'Altri T, et al. Te Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010;18:268-281.
12. Mai W, Meng H, Jin J, Wang L. Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol 2006;77:445-447. (Pubitemid 44483950)